Comera Life Sciences Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Comera Life Sciences Holdings has been growing earnings at an average annual rate of 46.1%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 81.8% per year.
Anahtar bilgiler
46.1%
Kazanç büyüme oranı
82.7%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 81.8% |
| Özkaynak getirisi | -8,809.8% |
| Net Marj | -935.0% |
| Son Kazanç Güncellemesi | 30 Sep 2023 |
Yakın geçmiş performans güncellemeleri
Recent updates
Comera Life Sciences rises on positive preclinical data from Sequrus study
Oct 18Comera life sciences expands woburn operations
Oct 04Comera Life Sciences announces up to $15M purchase agreement with Arena
Aug 31Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M
Aug 10Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans
May 27
Gelir ve Gider Dağılımı
Comera Life Sciences Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -9 | 7 | 1 |
| 30 Jun 23 | 1 | -10 | 8 | 1 |
| 31 Mar 23 | 1 | -18 | 10 | 1 |
| 31 Dec 22 | 1 | -18 | 9 | 2 |
| 30 Sep 22 | 1 | -17 | 10 | 2 |
| 30 Jun 22 | 0 | -15 | 8 | 1 |
| 31 Mar 22 | 0 | -8 | 6 | 2 |
| 31 Dec 21 | 0 | -5 | 4 | 2 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
Kaliteli Kazançlar: CMRA is currently unprofitable.
Büyüyen Kar Marjı: CMRA is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if CMRA's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare CMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CMRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: CMRA has a negative Return on Equity (-8809.78%), as it is currently unprofitable.